Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized‐controlled trial

Approved botulinum toxin A products require reconstitution. AbobotulinumtoxinA solution for injection is a ready‐to‐use liquid formulation of abobotulinumtoxinA.

[1]  B. Mohammadi,et al.  A long-term follow-up of botulinum toxin A in cervical dystonia , 2009, Neurological research.

[2]  W. Jost,et al.  Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia , 2012, Drugs.

[3]  R F Galbraith,et al.  A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.

[4]  A. Albanese,et al.  EFNS guidelines on diagnosis and treatment of primary dystonias , 2011, European journal of neurology.

[5]  S. Keam,et al.  Botulinum Toxin A (Dysport®) , 2011, Drugs.

[6]  M. Brin,et al.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. , 1999, Neurology.

[7]  A. Kupsch,et al.  Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  C. Sampaio,et al.  Botulinum toxin type B for cervical dystonia. , 2005, The Cochrane database of systematic reviews.

[9]  R. Barbano,et al.  Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. , 2008, Neurologic clinics.

[10]  J. Jankovic,et al.  Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia , 2011, Journal of the Neurological Sciences.

[11]  J. Jankovic,et al.  Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. , 2007, Parkinsonism & related disorders.

[12]  J. Hubble,et al.  AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies , 2013, Journal of Neural Transmission.

[13]  E. Pappert,et al.  Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial , 2008, Movement disorders : official journal of the Movement Disorder Society.

[14]  S. Factor,et al.  Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status , 2009, Movement disorders : official journal of the Movement Disorder Society.

[15]  N. Panjwani,et al.  Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use , 2008 .

[16]  M. Brin,et al.  Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia , 2012, Clinical neuropharmacology.

[17]  J. Jankovic,et al.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia , 2005, Neurology.

[18]  J. Jankovic,et al.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study , 2005, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Jankovic,et al.  Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. , 2010, Parkinsonism & related disorders.

[20]  M. Brin,et al.  Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia , 2014, BMC Neurology.

[21]  J. Jankovic,et al.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. , 1999, Neurology.